HCPCS Level II code U0002 represents non-CDC molecular diagnostic testing for SARS-CoV-2 that detects multiple viral targets. This code was introduced early in the COVID-19 pandemic to identify infections using assays that target several regions of the viral genome, enabling broader detection across variants. Nationally, accurate lab coding for COVID-19 tests affects surveillance, payer reimbursement, and data aggregation for public health reporting.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for U0002, benchmarks and typical site-of-service expectations for molecular laboratory testing, and discussion of the policy and billing implications tied to non-CDC multi-target assays. The summary highlights common modifiers associated with laboratory services and notes when additional technical or professional components may apply.

The publication details coding considerations, payer coverage patterns, and operational notes relevant to laboratories and health system billing teams. Where specific payer contract terms or payment rates are not available in the input, the document indicates that such data is not provided.